Remopharma
ActiveSummary
Remopharma has been active since 2008 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €2.2m and a net result of €241,142. Equity is growing by about 14% per year across the filed financial years. Its solvency ranks better than 73% of 12,650 sector peers (NACE 47, financial year 2025). The computed 12-month bankruptcy probability is 0.2% (very low).
Articles of association
What the company does
- DurationHow long the company exists; usually unlimited, so until it is dissolved.
- Unlimited
- Name clauseThe name the company operates under according to its articles.
- REMOPHARMA
- Registered office clauseThe region of the registered office; it decides among other things the language of official documents.
- One provision in the deed
Who represents it, and how
- Board ruleHow the board is made up, meets and takes decisions.
- “Met of zonder beperking van duur, natuurlijke personen of rechtspersonen, al dan niet aandeelhouder” (deed in Dutch)“Ontslag statutair bestuurder, alle aandeelhouders aanwezig of vertegenwoordigd” (deed in Dutch)
Meetings and financial year
- Annual meetingWhen the shareholders meet each year, among other things to approve the annual accounts.
- Last Friday of June at 19:00
Oversight and winding up
- Dissolution ruleWhen and by whom the company can be dissolved.
- “Algemene vergadering, zoals inzake statutenwijziging” (deed in Dutch)